OTC · PBSV
Pharma-Bio Serv, Inc.
$0.52$0.00 (0.0%)
Pharma-Bio Serv, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
Loading market information…
OTC · NUMIF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Numinus Wellness Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Numinus Wellness Inc.’s next earnings report is currently expected on Feb 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Numinus Wellness Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Numinus Wellness Inc. is dedicated to pioneering and delivering psychedelic-assisted psychotherapy, with the overarching goal of reshaping the mental healthcare landscape. The company's operations are segmented into two primary divisions: Salvation Botanicals and Numinus Health. Salvation Botanicals provides comprehensive laboratory services focused on psychedelics, encompassing cultivation, analytical testing, product research and development, and various ancillary supports. Additionally, this division offers both full-suite and bespoke testing for cannabis products. Numinus Health concentrates on promoting healing, connection, and personal growth through a range of supportive therapies and advanced technologies. This division specializes in addressing mental health challenges and substance abuse, delivering services including psychotherapy, counselling, neurofeedback, physiotherapy, and other therapeutic modalities. Furthermore, Numinus Health equips practitioners with vital training, facilities, and operational resources. The company's headquarters are situated in Vancouver, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Apr 12, 2024 | -$0.02-66.3% vs estimate | $606.19K-84.85% vs estimate |
|---|
| Q1 2024 | Jan 15, 2024 | -$0.01+16.35% vs estimate | $4.39M-4.24% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.52$0.00 (0.0%)
Pharma-Bio Serv, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
CA$0.08-CA$0.01 (-5.88%)
VentriPoint Diagnostics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 57.89% below the high.
$1,025.00$0.00 (0.0%)
Avem Health Partners, Inc.: Healthcare · Medical - Care Facilities.
$0.02-$0.00 (-1.32%)
ALR Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.78% below the high.
£0.01£0.00 (0.0%)
CelLBxHealth plc’s quoted price sits in the lower half of its reported 52-week range, 77.68% below the high.
$0.08$0.00 (0.0%)
EOM Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.22% below the high.
$0.02$0.00 (0.0%)
Herbal Dispatch Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.17% below the high.
$0.01$0.00 (0.0%)
Sirona Biochem Corp.’s quoted price sits in the lower half of its reported 52-week range, 57.85% below the high.
